Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Intravenous bolus topotecan in patients with myelodysplastic syndrome
Autore:
Seiter, K; Liu, DL; Feldman, EJ; Siddiqui, AD; Hoang, A; Baskind, P; Kancherla, R; Ahmed, T;
Indirizzi:
New York Med Coll, Dept Med, Zalmen A Arlin Canc Inst, Valhalla, NY 10595 USA New York Med Coll Valhalla NY USA 10595 Canc Inst, Valhalla, NY 10595 USA
Titolo Testata:
LEUKEMIA & LYMPHOMA
fascicolo: 5, volume: 42, anno: 2001,
pagine: 963 - 968
SICI:
1042-8194(200109/10)42:5<963:IBTIPW>2.0.ZU;2-V
Fonte:
ISI
Lingua:
ENG
Soggetto:
TOPOISOMERASE-I-INHIBITOR; CHRONIC MYELOMONOCYTIC LEUKEMIA; REFRACTORY ACUTE-LEUKEMIA; PHASE-I; CYTARABINE; CANCER;
Keywords:
myelodysplastic syndrome; topotecan; bolus; MDS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
11
Recensione:
Indirizzi per estratti:
Indirizzo: Seiter, K New York Med Coll, Dept Med, Zalmen A Arlin Canc Inst, Room 250 Munger Pavilion, Valhalla, NY 10595 USA New York Med Coll Room 250 Munger Pavilion Valhalla NY USA 10595
Citazione:
K. Seiter et al., "Intravenous bolus topotecan in patients with myelodysplastic syndrome", LEUK LYMPH, 42(5), 2001, pp. 963-968

Abstract

We treated 16 patients with myelodysplastic syndromes with 24 courses of bolus topotecan. Patients received topotecan as a daily 15 minute infusion for 5 days at 3 dose levels (4.0 mg/m(2)/d, 2.0 mg/m(2)/d or 2.5 mg/m(2)/d). There was one complete response and one partial response (overall responserate 12%). Toxicity included myelosuppression, diarrhea, ileus and mucositis. There were 3 treatment-related deaths. The results of this schedule of topotecan appeared to be inferior to that reported with infusional topotecan in patients with MDS.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 26/01/20 alle ore 16:50:15